A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users

Addictive Behaviors

Volumn 37, Issue 10, 2012, Pages 1151-1157

  Nordfjærn, Trond ^a,b  

^a Department of Research and Development   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Alcohol; Anxiety; Benzodiazepine; Depression; Outcomes; Sleep

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FLUNITRAZEPAM; HYPNOTIC AGENT; MIDAZOLAM; NITRAZEPAM; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DATA BASE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; QUESTIONNAIRE; SELF REPORT; SLEEP DISORDER; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ANXIETY DISORDERS; BENZODIAZEPINES; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; SELF REPORT; SLEEP DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863224519     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2012.05.017     Document Type: Article

References (50)

1. American Psychiatric Association Practice guideline for the treatment of patients with panic disorder 2009, APA, Washington, DC. 2nd ed.
2. Baldwin D., Woods R., Lawson R., Taylor D. Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis. British Medical Journal 2011, 342:1-11.
3. Bateson A.N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Current Pharmaceutical Design 2002, 8:5-21.
4. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. Journal of Psychosomatic Research 2002, 52:69-77.
5. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprozalam in alleviating panic attacks: A meta-analysis. International Clinical Psychopharmacology 1995, 10:45-49.
6. Bramness J.G. Utfordringer ved bruk av benzodiazepiner og z-hypnotika til voksne og eldre (in Norwegian). Retrieved 01.03.2012 from. http://http://www.forebygging.no/Global/utfordringer%20vedr%20benzo.pdf.
7. Bramness J.G. Tiltak mot misbruk av vanedannende legemidler. Tidsskrift for Den Norske Laegeforening 2012, 132:409. (in Norwegian).
8. Bramness J.G., Sexton J.A. The basic pharmacoepidemiology of benzodiazepine use in Norway 2003-9. Norwegian Journal of Epidemiology 2011, 21:35-41.
9. Buchsbaum D.G., Buchanan R.G., Centor R.M., Schnoll S.H., Lawton M.J. Screening for alcohol abuse using CAGE scores and likelihood ratios. Annals of Internal Medicine 1991, 155:774-777.
10. Buffett-Jerrott S.E., Stewart S.H. Cognitive and sedative effects of benzodiazepine use. Current Pharmaceutical Design 2002, 8:45-58.
11. Byles J.E., Mishra G.D., Harris M.A., Nair K. The problems of sleep for older women: Changes in health outcomes. Age and Ageing 2003, 32:154-163.
12. Chouinard G.F., Annable L., Fontaine R., Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 1982, 77:229-233.
13. Cox B., Endler N., Lee P., Swinson R. A meta-analysis of treatments for panic disorder with agoraphobia: Impramine, alprazolam, and in vivo exposure. Journal of Behavior Therapy and Experimental Psychiatry 1992, 23:175-182.
14. Dunbar G.C., Perera M.H., Jenner F.A. Patterns of benzodiazepine use in Great Britain as measured by a general population survey. The British Journal of Psychiatry 1989, 155:836-841.
15. Ewing J.A. Detecting alcoholism: The CAGE questionaire. Journal of the American Medical Association 1984, 252:1905-1907.
16. Fang S.-Y., Chen C.-Y., Chang I.S., Wu C.H.E., Chang C.-M., Lin K.-M. Predictors of the incidence and discontinuation of long-term use of Benzodiazepines: A population-based study. Drug and Alcohol Dependence 2009, 104:140-146.
17. Fedoroff I.C., Taylor S. Psychological and pharmacological treatments of social phobia: A meta-analysis. Journal of Clinical Psychopharmacology 2001, 21:311-324.
18. Gould R.A., Otto M.W., Pollack M.H., Yap L. Cognitive behavioural and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behaviour Therapy 1997, 28:285-305.
19. Greenblatt D.J., Harmatz J.S., Shader R.I. Psychotropic drug prescribing in the United States. Journal of Clinical Psychopharmacology 2011, 31:1-3.
20. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. The Journal of Clinical Psychiatry 2005, 66(Suppl. 9):31-41.
21. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals-Implications for problems of long-term use and abuse. Psychopharmacology 1997, 134:1-37.
22. Hair J.F., Anderson R.E., Tatham R.L., Black W.C. Multivariate data analysis 1998, Prentice-Hall, Upper Saddle River, New York.
23. Hartz I., Tverdal A., Skurtveit S. Langtidsbruk av benzodiazpiner i kombinasjon med opioider og z-hypnotika blant uføretrygdede i Norge. Norsk Farmaceutisk Tidsskrift 2011, 4:24-28. (in Norwegian).
24. Holbrook A.M., Crowther R., Lotter A., Cheng C., King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000, 162:225-233.
25. Holmen J., Midthjell K., Krüger Ø., Langhammer A., Holmen T.L., Bratberg G.H., et al. The Nord-Trøndelag health study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003, 13:19-32.
26. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Begaud B., Vedoux H., et al. Patterns and correlates of benzodiazepine use in the French general population. European Journal of Clinical Pharmacology 2004, 60:523-529.
27. Madhusoodanan S., Bogunovic O.J. Safety of benzodiazepines in the geriatric population. Expert Opinion on Drug Safety 2004, 3:485-493.
28. Magrini N., Vaccheri A., Parma E., D'Alessandro R., Bottoni A., Occhionero M., et al. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. European Journal of Clinical Pharmacology 1996, 50:19-25.
29. Martin C.R. What does the hospital anxiety and depression scale (HADS) really measure in Liaison psychiatry settings?. Current Psychiatry Reviews 2005, 1:69-73.
30. Mayfield D., McLeod G., Hall P. The Cage questionnaire: Validation of a new alcoholism screening instrument. The American Journal of Psychiatry 1974, 1121-1123.
31. Mellinger G.D., Balter M.B., Uhlenhuth E.H. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA : The Journal of the American Medical Association 1984, 251:375-379.
32. Mellingsæther T.C., Bramness J.G., Slørdal L. Er z-hypnotika bedre og tryggere sovemedisiner enn benzodiazepiner. Tidsskrift for Den Norske Laegeforening 2006, 126:2954-2960. (in Norwegian).
33. Michelini S., Cassano G.B., Frare F., Perugi G. Long-term use of benzodiazepines: Tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996, 29:127-134.
34. Moylan S., Staples J., Ward S.A., Rogerson J., Stein D.J., Berk M. The efficacy and safety of alprazolam versus other Benzodiazepines in the treatment of panic disorder. Journal of Clinical Psychopharmacology 2011, 31:647-652.
35. Mykletun A., Bjerkeset O., Øverland S., Prince M., Dewey M., Stewart R. Levels of anxiety and depression as predictors of mortality: The HUNT study. The British Journal of Psychiatry 2009, 195:118-125.
36. Neckelmann D., Mykletun A., Dahl A.A. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007, 30:873-880.
37. Neutel C.I., Walop W., Patten S.B. Can continuing benzodiazepine use be predicted?. The Canadian Journal of Clinical Pharmacology 2003, 10:202-206.
38. Nilsen E., Bachs L., Bjørner T., Høiseth G., Johnsen J., Ørbeck A.L., et al. Benzodiazepiner i behandling av personer med rusmiddelproblemer. Report from the Norwegian Knowledge Centre for the Health Services 2007, nr. 06. (in Norwegian).
39. Nordfjærn, T., Bjerkeset, O., Bratberg, G., Moylan, S., Berk, M., & Gråwe, R. W. (submitted for publication). Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. Drug and alcohol dependence.
40. Nowell P.D., Mazumdar S., Buysse D.J., Dew M.A., Reynolds C.F., Kupfer D.J. Benzodiazepines and zolpidem for chronic insomnia. JAMA : The Journal of the American Medical Association 1997, 278:2170-2177.
41. Nunnally J.C. Psychometric theory 1978, McGraw-Hill, New York.
42. Pariente A., Dartigues J.F., Benichou J., Letenneur L., Moore N., Fourrier Reglat-A Benzodiazepines and injurious falls in community dwelling elders. Drugs & Aging 2008, 25:61-70.
43. Shader R.I., Greenblatt D.J. Some current treatment options for symptoms of anxiety. The Journal of Clinical Psychiatry 1983, 44:21-30.
44. Smink B., Egberts A., Lusthof K., Uges D., de Gier J. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010, 24:639-653.
45. Sylvestre M.P., Abrahamowicz M., Capek R., Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. International Psychogeriatrics 2011, 8:1-10.
46. Vasile R.G., Bruce S.E., Goisman R.B., Pagano M., Keller M.B. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depression and Anxiety 2005, 22:59-67.
47. Verispan L. Vector One: National (VONA) Health Analytics Data 2008, Retrieved 22.08.2011, Substance Abuse and Mental Health Services Administration, http://nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt.
48. World Health Organisation WHO Collaborating Centre for Drug Statisticsrfurl http://www.whocc.no/
49. Wu S.-I., Huang H.-C., Liu S.-I., Huang C.-R., Sun F.-J., Chang T.-Y., et al. Validation and comparison of alcohol screening instruments for identifying hazardous drinking in hospitalized patients in Taiwan. Alcohol and Alcoholism 2008, 43:577-582.
50. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983, 67:361-370.